Crizotinib and Buprenorphine: Interaction Details
- Buprenorphine
- ButransBelbucaSublocade +2 more
- Crizotinib
- Xalkori
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Crizotinib and Buprenorphine interaction:
Buprenorphine
- Butrans
- Belbuca
- Sublocade
- Buprenex
- Brixadi
What Happens When You Take Crizotinib With Buprenorphine
What can happen when they are taken together (rated Major)
An increased risk of , increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
When buprenorphine is used together with a , plasma buprenorphine concentrations rise, which can lead to prolonged effects such as . Drugs that alter cardiac conduction also add to the risk of QT prolongation, so if such agents are given together, the patient should be watched closely for a lengthening of the .
Lowering the buprenorphine dose should be considered until drug effects have stabilized, with frequent monitoring for and respiratory depression. If a CYP3A4 inhibitor is stopped in a patient on buprenorphine, a buprenorphine dose increase may be considered until effects are stable, and the patient should be monitored for signs of opioid withdrawal.1
Should the dose be impossible to adjust once the CYP3A4 inhibitor is no longer present, the patient should be moved back to a buprenorphine formulation that allows finer dose adjustment. For patients switched from transmucosal buprenorphine taken with CYP3A4 , monitoring is needed to confirm that the plasma buprenorphine level achieved with subQ buprenorphine is sufficient.
For patients already receiving subQ buprenorphine who need a CYP3A4 inhibitor, watch for signs and symptoms of over-medication. If buprenorphine toxicity or overdose signs and symptoms appear and the drug cannot be reduced or stopped, the buprenorphine dose should be reduced. If the available doses do not allow the desired dose to be reached, treatment should be discontinued and the patient treated with a buprenorphine formulation that permits more precise dose adjustment.2
The Crizotinib and Buprenorphine Interaction, Explained
Taking these two together can make buprenorphine stronger and can affect your heart rhythm. Crizotinib (a cancer medicine) slows the liver enzyme () that helps clear buprenorphine, so more of it can stay in your body. That can mean extra sleepiness, slowed breathing, or other side effects. Both medicines can also lengthen the , a measure of your heart's electrical rhythm, which raises the chance of an irregular heartbeat.
Don't change or stop either medicine on your own. Your pharmacist or doctor can adjust your buprenorphine dose and check on you more closely. Tell them right away if you feel very drowsy, dizzy, faint, or notice a racing or fluttering heartbeat.
Mechanism: Crizotinib inhibits , the main pathway for buprenorphine N-dealkylation, so buprenorphine exposure (/) is expected to rise. Both agents also prolong the , so the effect is (PD). Buprenorphine is active itself (not a ), so increases effect.
- Risks: prolonged , , and or .
- Evidence: probable; onset unspecified; severity major.
- Management: obtain an and monitor for QT prolongation, and correct electrolytes. Consider reducing the buprenorphine dose until effects stabilize, and monitor frequently for sedation and respiratory depression.
- If crizotinib is stopped, consider a buprenorphine dose increase and monitor for withdrawal.
- If the dose can't be adjusted, consider a formulation allowing finer dose .
See the 3 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Crizotinib and Buprenorphine Interact
The likely mechanism
; of -mediated of buprenorphine
How to Manage the Crizotinib and Buprenorphine Interaction
Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. Your team may monitor you more closely, including heart rhythm checks (), and may adjust and individualize your buprenorphine dose until your response is steady.
- Report excess sleepiness, slow or shallow breathing, confusion, fainting, or palpitations promptly.
- If crizotinib is ever stopped, tell your team, since your buprenorphine dose may need another look and you may need to watch for withdrawal symptoms.
- If your current product doesn't allow small dose changes, your prescriber may suggest a different buprenorphine formulation.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Crizotinib or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
2 reports from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Voriconazole greatly increases the exposure to oral buprenorphine
In a study of healthy volunteers (N=12), of oral buprenorphine with voriconazole significantly raised the mean (0 to 18 hours) of buprenorphine 4.3-fold (from 0.43 to 2.1 nanograms (ng) x hr/mL), raised 3.9-fold (from 0.057 to 0.22 ng/mL), and lengthened the (from 9.1 to 14.5 hours) and urinary (from 0.31 to 0.73 L/hr). Voriconazole also significantly increased exposure to the active , norbuprenorphine, by almost 4-fold for AUC(0 to 18 hours) and 3.3-fold for Cmax, and reduced its clearance (from 7.2 to 2.9 L/hr).
Mild dizziness and nausea were reported by subjects during both phases. Subjects received either placebo or voriconazole 400 mg twice daily on day 1 and 200 mg twice daily on days 2 to 5, followed by a 4-week washout period before crossing over to the other regimen. On the fifth day, all subjects received a single dose of buprenorphine 0.2 mg orally, or 3.6 mg during the placebo phase.3
-
Report 2 · Study title
Prescribing information: BRIXADI subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection
The influence of coadministered on buprenorphine exposure has not been studied in subjects treated with subQ buprenorphine; however, such interactions have been demonstrated in studies of transmucosal buprenorphine. The effects of buprenorphine may depend on the route of administration.2
Crizotinib and Buprenorphine: Common Questions
How serious is the Crizotinib and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Crizotinib and Buprenorphine interaction managed?
Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. Your team may monitor you more closely, including heart rhythm checks (), and may adjust and individualize your buprenorphine dose until your response is steady. Report excess sleepiness, slow or shallow breathing, confusion, fainting, or palpitations promptly. If crizotinib is ever stopped, tell your te… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Ask About the Crizotinib and Buprenorphine Interaction
Ask in your own words about taking Crizotinib and Buprenorphine together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (3)
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Fihlman M, Hemmila T, Hagelberg NM, et al: Voriconazole greatly increases the exposure to oral buprenorphine. Eur J Clin Pharmacol 2018; 74(12):1615-1622. PubMed
Other Serious Interactions of Crizotinib and Buprenorphine
Also serious with Buprenorphine
- DronedaroneContraindicated
- FluconazoleContraindicated
- IsocarboxazidContraindicated
- KetoconazoleContraindicated
Also serious with Crizotinib
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Buprenorphine
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- KavaMajor
- WineMajor
- 1,4-butanediolMajor
- BeerMajor
- Gamma-hydroxybutyrate (GHB)Major
- + 210 more
With Crizotinib
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- American HelleboreMajor
- ArsenicMajor
- CesiumMajor
- EphedraMajor
- Sida CordifoliaMajor
- + 154 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven. This interaction.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.